Does the media refer more to ATOS or CLGN?

In the previous week, Atossa Genetics had 1 more articles in the media than CollPlant Biotechnologies. MarketBeat recorded 3 mentions for Atossa Genetics and 2 mentions for CollPlant Biotechnologies. CollPlant Biotechnologies' average media sentiment score of 0.91 beat Atossa Genetics' score of 0.61 indicating that CollPlant Biotechnologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Atossa Genetics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CollPlant Biotechnologies 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to KYNB or CLGN?

In the previous week, Kyntra Bio had 3 more articles in the media than CollPlant Biotechnologies. MarketBeat recorded 5 mentions for Kyntra Bio and 2 mentions for CollPlant Biotechnologies. CollPlant Biotechnologies' average media sentiment score of 0.91 beat Kyntra Bio's score of 0.16 indicating that CollPlant Biotechnologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kyntra Bio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral CollPlant Biotechnologies 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor CLGN or ESLA?

In the previous week, Estrella Immunopharma had 1 more articles in the media than CollPlant Biotechnologies. MarketBeat recorded 3 mentions for Estrella Immunopharma and 2 mentions for CollPlant Biotechnologies. Estrella Immunopharma's average media sentiment score of 1.25 beat CollPlant Biotechnologies' score of 0.91 indicating that Estrella Immunopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CollPlant Biotechnologies 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Estrella Immunopharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor JSPR or CLGN?

In the previous week, Jasper Therapeutics had 2 more articles in the media than CollPlant Biotechnologies. MarketBeat recorded 4 mentions for Jasper Therapeutics and 2 mentions for CollPlant Biotechnologies. CollPlant Biotechnologies' average media sentiment score of 0.91 beat Jasper Therapeutics' score of 0.47 indicating that CollPlant Biotechnologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Jasper Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral CollPlant Biotechnologies 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

CollPlant Biotechnologies (CLGN) Competitors

$4.13 +0.22 (+5.63%)

Closing price 10/14/2026 04:00 PM Eastern

Extended Trading

$3.99 -0.14 (-3.39%)

As of 07:03 AM Eastern

Compare

CLGN vs. ATOS, KYNB, NXTC, ESLA, and JSPR

Should you buy CollPlant Biotechnologies stock or one of its competitors? CollPlant Biotechnologies's main competitors and comparable companies include Atossa Genetics (ATOS), Kyntra Bio (KYNB), NextCure (NXTC), Estrella Immunopharma (ESLA), and Jasper Therapeutics (JSPR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does CollPlant Biotechnologies compare to Atossa Genetics?

Atossa Genetics (NASDAQ:ATOS) and CollPlant Biotechnologies (NASDAQ:CLGN) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, risk, earnings, dividends and media sentiment.

12.7% of Atossa Genetics shares are owned by institutional investors. Comparatively, 21.7% of CollPlant Biotechnologies shares are owned by institutional investors. 9.8% of Atossa Genetics shares are owned by insiders. Comparatively, 9.6% of CollPlant Biotechnologies shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Atossa Genetics had 1 more articles in the media than CollPlant Biotechnologies. MarketBeat recorded 3 mentions for Atossa Genetics and 2 mentions for CollPlant Biotechnologies. CollPlant Biotechnologies' average media sentiment score of 0.91 beat Atossa Genetics' score of 0.61 indicating that CollPlant Biotechnologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Atossa Genetics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CollPlant Biotechnologies	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Atossa Genetics has a net margin of 0.00% compared to CollPlant Biotechnologies' net margin of -678.37%. Atossa Genetics' return on equity of -102.99% beat CollPlant Biotechnologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atossa Genetics	N/A	-102.99%	-85.78%
CollPlant Biotechnologies	-678.37%	-298.21%	-167.83%

CollPlant Biotechnologies has higher revenue and earnings than Atossa Genetics. Atossa Genetics is trading at a lower price-to-earnings ratio than CollPlant Biotechnologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atossa Genetics	N/A	N/A	-$34.77M	-$3.11	N/A
CollPlant Biotechnologies	$2.37M	3.29	-$11.49M	-$13.59	N/A

Atossa Genetics has a beta of 1.27, indicating that its stock price is 27% more volatile than the broader market. Comparatively, CollPlant Biotechnologies has a beta of 1.77, indicating that its stock price is 77% more volatile than the broader market.

Atossa Genetics currently has a consensus target price of $20.33, indicating a potential upside of 631.41%. CollPlant Biotechnologies has a consensus target price of $120.00, indicating a potential upside of 2,805.57%. Given CollPlant Biotechnologies' higher possible upside, analysts plainly believe CollPlant Biotechnologies is more favorable than Atossa Genetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atossa Genetics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
CollPlant Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Summary

Atossa Genetics beats CollPlant Biotechnologies on 8 of the 14 factors compared between the two stocks.

How does CollPlant Biotechnologies compare to Kyntra Bio?

Kyntra Bio (NASDAQ:KYNB) and CollPlant Biotechnologies (NASDAQ:CLGN) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, media sentiment, valuation, profitability and analyst recommendations.

72.7% of Kyntra Bio shares are held by institutional investors. Comparatively, 21.7% of CollPlant Biotechnologies shares are held by institutional investors. 4.2% of Kyntra Bio shares are held by insiders. Comparatively, 9.6% of CollPlant Biotechnologies shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Kyntra Bio had 3 more articles in the media than CollPlant Biotechnologies. MarketBeat recorded 5 mentions for Kyntra Bio and 2 mentions for CollPlant Biotechnologies. CollPlant Biotechnologies' average media sentiment score of 0.91 beat Kyntra Bio's score of 0.16 indicating that CollPlant Biotechnologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kyntra Bio	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
CollPlant Biotechnologies	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Kyntra Bio has a net margin of 2,199.13% compared to CollPlant Biotechnologies' net margin of -678.37%. Kyntra Bio's return on equity of 0.00% beat CollPlant Biotechnologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kyntra Bio	2,199.13%	N/A	-47.27%
CollPlant Biotechnologies	-678.37%	-298.21%	-167.83%

Kyntra Bio has a beta of 1.05, suggesting that its share price is 5% more volatile than the broader market. Comparatively, CollPlant Biotechnologies has a beta of 1.77, suggesting that its share price is 77% more volatile than the broader market.

Kyntra Bio has higher revenue and earnings than CollPlant Biotechnologies. CollPlant Biotechnologies is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kyntra Bio	$6.44M	3.50	$183.45M	$45.30	0.12
CollPlant Biotechnologies	$2.37M	3.29	-$11.49M	-$13.59	N/A

Kyntra Bio presently has a consensus target price of $36.80, indicating a potential upside of 560.68%. CollPlant Biotechnologies has a consensus target price of $120.00, indicating a potential upside of 2,805.57%. Given CollPlant Biotechnologies' higher probable upside, analysts clearly believe CollPlant Biotechnologies is more favorable than Kyntra Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kyntra Bio	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.43
CollPlant Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Summary

Kyntra Bio beats CollPlant Biotechnologies on 11 of the 15 factors compared between the two stocks.

How does CollPlant Biotechnologies compare to NextCure?

CollPlant Biotechnologies (NASDAQ:CLGN) and NextCure (NASDAQ:NXTC) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, institutional ownership, risk, profitability, analyst recommendations and dividends.

NextCure has a net margin of 0.00% compared to CollPlant Biotechnologies' net margin of -678.37%. NextCure's return on equity of -154.62% beat CollPlant Biotechnologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CollPlant Biotechnologies	-678.37%	-298.21%	-167.83%
NextCure	N/A	-154.62%	-100.19%

CollPlant Biotechnologies has higher revenue and earnings than NextCure. NextCure is trading at a lower price-to-earnings ratio than CollPlant Biotechnologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CollPlant Biotechnologies	$2.37M	3.29	-$11.49M	-$13.59	N/A
NextCure	N/A	N/A	-$55.84M	-$8.70	N/A

CollPlant Biotechnologies has a beta of 1.77, indicating that its share price is 77% more volatile than the broader market. Comparatively, NextCure has a beta of 1.33, indicating that its share price is 33% more volatile than the broader market.

21.7% of CollPlant Biotechnologies shares are owned by institutional investors. Comparatively, 42.7% of NextCure shares are owned by institutional investors. 9.6% of CollPlant Biotechnologies shares are owned by company insiders. Comparatively, 11.9% of NextCure shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

CollPlant Biotechnologies presently has a consensus target price of $120.00, indicating a potential upside of 2,805.57%. NextCure has a consensus target price of $19.00, indicating a potential upside of 188.75%. Given CollPlant Biotechnologies' higher possible upside, analysts plainly believe CollPlant Biotechnologies is more favorable than NextCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CollPlant Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
NextCure	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, CollPlant Biotechnologies and CollPlant Biotechnologies both had 2 articles in the media. CollPlant Biotechnologies' average media sentiment score of 0.91 beat NextCure's score of 0.41 indicating that CollPlant Biotechnologies is being referred to more favorably in the media.

Company	Overall Sentiment
CollPlant Biotechnologies	Positive
NextCure	Neutral

Summary

NextCure beats CollPlant Biotechnologies on 8 of the 13 factors compared between the two stocks.

How does CollPlant Biotechnologies compare to Estrella Immunopharma?

CollPlant Biotechnologies (NASDAQ:CLGN) and Estrella Immunopharma (NASDAQ:ESLA) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, earnings, risk, valuation and dividends.

21.7% of CollPlant Biotechnologies shares are held by institutional investors. Comparatively, 0.3% of Estrella Immunopharma shares are held by institutional investors. 9.6% of CollPlant Biotechnologies shares are held by insiders. Comparatively, 5.8% of Estrella Immunopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

CollPlant Biotechnologies has higher revenue and earnings than Estrella Immunopharma. Estrella Immunopharma is trading at a lower price-to-earnings ratio than CollPlant Biotechnologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CollPlant Biotechnologies	$2.37M	3.29	-$11.49M	-$13.59	N/A
Estrella Immunopharma	N/A	N/A	-$13.06M	-$0.24	N/A

In the previous week, Estrella Immunopharma had 1 more articles in the media than CollPlant Biotechnologies. MarketBeat recorded 3 mentions for Estrella Immunopharma and 2 mentions for CollPlant Biotechnologies. Estrella Immunopharma's average media sentiment score of 1.25 beat CollPlant Biotechnologies' score of 0.91 indicating that Estrella Immunopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CollPlant Biotechnologies	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Estrella Immunopharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

CollPlant Biotechnologies has a beta of 1.77, indicating that its share price is 77% more volatile than the broader market. Comparatively, Estrella Immunopharma has a beta of 0.93, indicating that its share price is 7% less volatile than the broader market.

Estrella Immunopharma has a net margin of 0.00% compared to CollPlant Biotechnologies' net margin of -678.37%. Estrella Immunopharma's return on equity of 0.00% beat CollPlant Biotechnologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CollPlant Biotechnologies	-678.37%	-298.21%	-167.83%
Estrella Immunopharma	N/A	N/A	-328.72%

CollPlant Biotechnologies presently has a consensus target price of $120.00, suggesting a potential upside of 2,805.57%. Estrella Immunopharma has a consensus target price of $8.00, suggesting a potential upside of 2,416.51%. Given CollPlant Biotechnologies' higher probable upside, analysts plainly believe CollPlant Biotechnologies is more favorable than Estrella Immunopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CollPlant Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Estrella Immunopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

CollPlant Biotechnologies beats Estrella Immunopharma on 8 of the 15 factors compared between the two stocks.

How does CollPlant Biotechnologies compare to Jasper Therapeutics?

Jasper Therapeutics (NASDAQ:JSPR) and CollPlant Biotechnologies (NASDAQ:CLGN) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, earnings, risk, media sentiment and valuation.

Jasper Therapeutics currently has a consensus price target of $7.33, suggesting a potential upside of 1,363.74%. CollPlant Biotechnologies has a consensus price target of $120.00, suggesting a potential upside of 2,805.57%. Given CollPlant Biotechnologies' higher possible upside, analysts clearly believe CollPlant Biotechnologies is more favorable than Jasper Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jasper Therapeutics	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38
CollPlant Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

In the previous week, Jasper Therapeutics had 2 more articles in the media than CollPlant Biotechnologies. MarketBeat recorded 4 mentions for Jasper Therapeutics and 2 mentions for CollPlant Biotechnologies. CollPlant Biotechnologies' average media sentiment score of 0.91 beat Jasper Therapeutics' score of 0.47 indicating that CollPlant Biotechnologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Jasper Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
CollPlant Biotechnologies	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

79.9% of Jasper Therapeutics shares are held by institutional investors. Comparatively, 21.7% of CollPlant Biotechnologies shares are held by institutional investors. 3.9% of Jasper Therapeutics shares are held by company insiders. Comparatively, 9.6% of CollPlant Biotechnologies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Jasper Therapeutics has a net margin of 0.00% compared to CollPlant Biotechnologies' net margin of -678.37%. CollPlant Biotechnologies' return on equity of -298.21% beat Jasper Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jasper Therapeutics	N/A	-884.17%	-143.83%
CollPlant Biotechnologies	-678.37%	-298.21%	-167.83%

CollPlant Biotechnologies has higher revenue and earnings than Jasper Therapeutics. Jasper Therapeutics is trading at a lower price-to-earnings ratio than CollPlant Biotechnologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jasper Therapeutics	N/A	N/A	-$75.80M	-$1.59	N/A
CollPlant Biotechnologies	$2.37M	3.29	-$11.49M	-$13.59	N/A

Jasper Therapeutics has a beta of 3.16, indicating that its stock price is 216% more volatile than the broader market. Comparatively, CollPlant Biotechnologies has a beta of 1.77, indicating that its stock price is 77% more volatile than the broader market.

Summary

Jasper Therapeutics beats CollPlant Biotechnologies on 8 of the 15 factors compared between the two stocks.

Get CollPlant Biotechnologies News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CLGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CLGN vs. The Competition

Export

Metric	CollPlant Biotechnologies	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$7.39M	$3.85B	$7.19B	$13.18B
Dividend Yield	N/A	3.65%	2.52%	19.60%
P/E Ratio	-0.30	11.09	221.68	20.80
Price / Sales	3.29	1,089.48	546.08	66.79
Price / Cash	N/A	119.79	76.68	52.75
Price / Book	0.87	16.26	10.41	5.92
Net Income	-$11.49M	-$22.69M	$3.50B	$380.90M
7 Day Performance	4.03%	-5.80%	-3.49%	-3.90%
1 Month Performance	21.47%	-12.85%	-7.76%	-6.42%
1 Year Performance	-82.79%	3.03%	0.83%	-6.02%

CollPlant Biotechnologies Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CLGN CollPlant Biotechnologies	2.6709 of 5 stars	$4.13 +5.6%	$120.00 +2,805.6%	-82.2%	$7.39M	$2.37M	N/A	39	Gap Up
ATOS Atossa Genetics	1.8318 of 5 stars	$2.47 +0.6%	$20.33 +724.9%	-82.0%	$24.60M	N/A	N/A	14
KYNB Kyntra Bio	3.2752 of 5 stars	$5.97 +0.2%	$37.25 +523.8%	N/A	$24.19M	$6.44M	0.13	570	Analyst Downgrade
NXTC NextCure	2.7849 of 5 stars	$5.68 0.0%	$19.00 +234.6%	-2.1%	$20.50M	N/A	N/A	40	Short Interest Increase
ESLA Estrella Immunopharma	1.7177 of 5 stars	$0.44 +2.3%	$8.00 +1,722.3%	-81.1%	$19.10M	N/A	N/A	N/A	News Coverage Positive News Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CLGN) was last updated on 10/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CollPlant Biotechnologies (CLGN) Competitors

CLGN vs. ATOS, KYNB, NXTC, ESLA, and JSPR

How does CollPlant Biotechnologies compare to Atossa Genetics?

Summary

How does CollPlant Biotechnologies compare to Kyntra Bio?

Summary

How does CollPlant Biotechnologies compare to NextCure?

Summary

How does CollPlant Biotechnologies compare to Estrella Immunopharma?

Summary

How does CollPlant Biotechnologies compare to Jasper Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLGN vs. The Competition

CollPlant Biotechnologies Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CollPlant Biotechnologies (CLGN) Competitors

CLGN vs. ATOS, KYNB, NXTC, ESLA, and JSPR

How does CollPlant Biotechnologies compare to Atossa Genetics?

Do institutionals & insiders have more ownership in ATOS or CLGN?

Does the media refer more to ATOS or CLGN?

Is ATOS or CLGN more profitable?

Which has higher earnings & valuation, ATOS or CLGN?

Which has more volatility and risk, ATOS or CLGN?

Do analysts rate ATOS or CLGN?

Summary

How does CollPlant Biotechnologies compare to Kyntra Bio?

Do insiders and institutionals believe in KYNB or CLGN?

Does the media refer more to KYNB or CLGN?

Is KYNB or CLGN more profitable?

Which has more risk & volatility, KYNB or CLGN?

Which has stronger earnings & valuation, KYNB or CLGN?

Do analysts prefer KYNB or CLGN?

Summary

How does CollPlant Biotechnologies compare to NextCure?

Is CLGN or NXTC more profitable?

Which has preferable earnings & valuation, CLGN or NXTC?

Which has more risk and volatility, CLGN or NXTC?

Do insiders & institutionals believe in CLGN or NXTC?

Do analysts prefer CLGN or NXTC?

Does the media favor CLGN or NXTC?

Summary

How does CollPlant Biotechnologies compare to Estrella Immunopharma?

Do institutionals and insiders have more ownership in CLGN or ESLA?

Which has stronger valuation and earnings, CLGN or ESLA?

Does the media favor CLGN or ESLA?

Which has more volatility and risk, CLGN or ESLA?

Is CLGN or ESLA more profitable?

Do analysts prefer CLGN or ESLA?

Summary

How does CollPlant Biotechnologies compare to Jasper Therapeutics?

Do analysts prefer JSPR or CLGN?

Does the media favor JSPR or CLGN?

Do insiders and institutionals have more ownership in JSPR or CLGN?

Is JSPR or CLGN more profitable?

Which has better earnings & valuation, JSPR or CLGN?

Which has more risk & volatility, JSPR or CLGN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLGN vs. The Competition

CollPlant Biotechnologies Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools